TERBUTALINE SULFATE

Post-LOE

terbutaline sulfate

Lavipharm

ANDAORALTABLET

Approved

Jun 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

TERBUTALINE SULFATE (terbutaline sulfate) by Lavipharm is clinical pharmacology in vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. Approved for asthma. First approved in 2020.

Drug data last refreshed 18h ago

Mechanism of Action

CLINICAL PHARMACOLOGY In vitro and in vivo pharmacologic studies have demonstrated that terbutaline exerts a preferential effect on beta 2 -adrenergic receptors. While it is recognized that beta 2 -adrenergic receptors are the predominant receptors in bronchial smooth muscle, data indicate that…

Worked on TERBUTALINE SULFATE at Lavipharm? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

TERBUTALINE SULFATE

Mechanism of Action

Indications (1)